Welcome to the resource library, where you can find strategy, research and examples of promising practice in medicine, commissioning and drug services for hepatitis C
Resources
Showing 1 to 10 of 31 resources
-
World Hepatitis Day 2018: Global Summary Report
This report, produced by the World Hepatitis Alliance, provides a comprehensive summary of international activity for World Hepatitis Day 2018. 144 countries, 93 governments and 53 WHO Country Offices took part across the six regions. Over 1,600 events were organised, 318,914 people attended events in their local community or country, and millions were reached online.UK, Rest of World 18 Dec 2018 Reports & Research PDF -
United Nations Common Position on Ending HIV, TB and Viral Hepatitis through Intersectoral Collaboration
This common position paper outlines shared principles and key actionable areas within and beyond the health sector to address HIV, tuberculosis and viral hepatitis in Europe and central Asia, and is signed by 14 UN organisations.Rest of World Reports & Research PDF -
Hepatitis B and C epidemiology in selected population groups in the EU/EEA
This report details the findings of a comparative analysis of existing hepatitis B/C testing guidelines and available data on the prevalence and incidence of HBV and HCV among at-risk population groups in EU/EEA countries, to outline the key at-risk groups for hepatitis B and C in EU and EEA countires.UK, Rest of World 30 Oct 2018 Reports & Research PDF -
R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
This research paper assesses the impact of (i) incentives for R&D based on providing Intellectual Property (IP) rights protection, (ii) market competition and (iii) other factors including healthcare policies on access to direct acting antivirals (DAA) for hepatitis C in Europe.UK, Rest of World Reports & Research PDF -
Public health guidance on active case finding of communicable diseases in prison settings
This document, produced by the European Centre for Disease Prevention and Control, provides guidance to EU/EEA member states on prevention and case-finding for communicable diseases, including hepatitis C, in prisons.UK, Rest of World Reports & Research, Strategy & Planning PDF -
Hepatitis B/C in the countries of the EU/ EEA: a systematic review of the prevalence among at-risk groups
This 2018 study provides estimates of hepatitis C (and hepatitis B) prevalence among people in prison, men who have sex with men (MSM) and people who inject drugs (PWID) in countries which are member states of the European Union and European Economic Area. This article has been republished by HCV Action under the terms of the Creative Commons license: http://creativecommons.org/licenses/by/4.0/UK, Rest of World Reports & Research PDF -
Annual Epidemiological Report for 2015 - Hepatitis C
Released in December 2017, the latest annual report from the European Centre for Disease Prevention and Control provides a comprehensive summary of hepatitis C surveillance data for EU/EEA countries in 2015, looking at epidemiology, trends and public health implications.UK, Rest of World Reports & Research PDF -
Road to Elimination: Barriers and Best Practices in Hepatitis C Management
This report provides an overview of the status of HCV care in Europe and Australia. Through literature review and country experts’ consultation conducted between November 2016 and March 2017, the report analyses the status of 11 countries, identifying and comparing key success factors and main barriers for each step of the HCV care cascade: (1) awareness and prevention; (2) testing and diagnosis; (3) linkage to care and access to qualified health services; (4) access to medication; and (5) monitoring and evaluation.UK, Rest of World Reports & Research, Strategy & Planning PDF -
Reduction in Liver Transplant Wait-Listing in the Era of Direct-Acting Antiviral Therapy
This paper analyses trends in liver transplant wait-listing to explore the potential impact of direct acting antiviral (DAA) treatments for hepatitis C on wait-listing registration. The authors conclude that the rate of liver transplant wait-listing for hepatitis C complicated by decompensated cirrhosis has decreased by over 30% in the era of DAA therapy. Further reductions in wait-listing are anticipated with increased testing, linkage to care, and access to DAA therapy.Rest of World Reports & Research PDF -
Hepatitis B and C testing activities, needs, and priorities in the EU/EEA
Hepatitis B and C virus infections are associated with a considerable burden of disease in Europe. The European Centre for Disease Prevention and Control undertook a survey to assess needs and priorities prior to developing guidance on testing and screening for hepatitis B and C in the EU/EEA, and to update the existing evidence on the burden of HBV/HCV morbidity and mortality across EU/EEA Member States.Rest of World Reports & Research PDF